<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
A Japanese health ministry panel has backed Moderna Inc’s (NASDAQ: MRNA) COVID-19 vaccine for emergency use in children aged between 12 to 17 years, paving the way for final approval by the ministry in the coming days. The panel recommended lowering the current age restriction of 18 and older without conducting an additional clinical trial in the country.
...read full article on Benzinga
